Furthermore, Gil et al (14) reported that a virus-coated CXCR4 antagonist is effective in the treatment of primary or metastatic breast cancer, functioning by disrupting the internal environment for tumor cell growth and inhibiting the vascularization and expression of CXCL12 and vascular endothelial growth factor (VEGF). This evidence concerns the gene CXCL12 and neoplasm.